Division of Arthritis and Rheumatic Diseases, and Department of Ophthalmology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., L647Ad, Portland, OR 97239, USA.
Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, Ghent 9000, Belgium.
Best Pract Res Clin Rheumatol. 2014 Oct;28(5):687-702. doi: 10.1016/j.berh.2014.10.018. Epub 2014 Nov 15.
The intestinal microbiota is firmly implicated not only in the pathogenesis of inflammatory bowel disease (IBD) but increasingly also in the development of inflammation at extraintestinal tissue sites. Significant clinical, genetic, immunological, and microbiological overlap exists between IBD and spondyloarthritis (SpA), which indicates that pathophysiological mechanisms are shared between these diseases and may center on the intestinal microbiota. Recently, culture-independent techniques have enabled the microbiota in health and disease to be described in increasing detail. Moreover, functional studies have identified myriad host effector and regulatory pathways that shape or are shaped by this microbial community. We consider the complex relationship between SpA pathogenesis and gut microbes, with a discussion of how manipulation of the gut microbiota itself may be a promising future target for SpA therapy.
肠道微生物群不仅与炎症性肠病 (IBD) 的发病机制密切相关,而且越来越多地与肠道外组织部位的炎症发展有关。IBD 和脊柱关节炎 (SpA) 之间存在显著的临床、遗传、免疫和微生物学重叠,这表明这些疾病具有共同的病理生理机制,其可能集中于肠道微生物群。最近,非培养技术使我们能够越来越详细地描述健康和疾病中的微生物群。此外,功能研究已经确定了无数宿主效应和调节途径,这些途径塑造或受这个微生物群落的影响。我们考虑了 SpA 发病机制与肠道微生物群之间的复杂关系,并讨论了如何操纵肠道微生物群本身可能成为 SpA 治疗的一个有前途的未来靶点。